About this trial
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.
Eligibility criteria
Qualifiers
Age 2 years and above;
Self-identified as African-American "Gullah" from the Sea Island region of South Carolina;
Have had at least 4 of the 11 diagnostic criteria for SLE as designated by the American College of Rheumatology (ACR), be a relative of a known SLE patient, or be an unrelated healthy Gullah control;
Ability to speak and understand English;
Disqualifiers
Race defined by participant as other than Black or African-American;
Being a prisoner, mentally ill patient, or institutionalized individual;
Unwilling or unable to give informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Medical University of South Carolina
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator